Key Details
Price
$5.80Annual ROE
-98.01%Beta
2.21Events Calendar
Next earnings date:
Mar 28, 2025Recent quarterly earnings:
Nov 14, 2024Recent annual earnings:
Mar 28, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Feb 23, 2022Analyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
PALO ALTO, Calif. , Feb. 4, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that senior management will present the Company's pipeline program exploring the treatment of glaucoma at the Glaucoma 360 New Horizons Forum 2025 on Friday, February 7, 2025, in San Francisco, CA.
Kodiak stock skyrockets 271% in six months on the back of positive updates from the tarcocimab program for treating retinal vascular diseases.
Kodiak stock surges as Jefferies upgrades it to a "BUY" rating based on the significant potential of its pipeline candidates for retinal disease indications.
Kodiak Sciences Inc. (KOD) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, KOD's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
PALO ALTO, Calif. , Nov. 11, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that management will present at the following upcoming investor conferences.
PALO ALTO, Calif. , Oct. 14, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today its participation in a presentation and panel at Innovate Retina 2024 on October 17, 2024, in Chicago, Illinois.
KOD is evaluating tarcocimab in a phase III diabetic retinopathy study, which is set to form the basis for a regulatory filing across three eye disease indications.
Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock?
Kodiak (KOD) reports a narrower-than-expected loss for the second quarter of 2024. The company provides updates regarding its pipeline development plans.
Kodiak Sciences (KOD) is evaluating its lead candidate, tarcocimab, in a late-stage study for diabetic retinopathy, which is expected to support a regulatory filing for three eye disease indications.
FAQ
- What is the ticker symbol for Kodiak Sciences?
- Does Kodiak Sciences pay dividends?
- What sector is Kodiak Sciences in?
- What industry is Kodiak Sciences in?
- What country is Kodiak Sciences based in?
- When did Kodiak Sciences go public?
- Is Kodiak Sciences in the S&P 500?
- Is Kodiak Sciences in the NASDAQ 100?
- Is Kodiak Sciences in the Dow Jones?
- When was Kodiak Sciences's last earnings report?
- When does Kodiak Sciences report earnings?
- Should I buy Kodiak Sciences stock now?